Spinal stimulation restored muscles wasted by rare genetic disorder
Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal stimulation.
neurodegenerative disease
Lots of drug companies talk about putting patients first — but this one actually did
When Amylyx Pharmaceuticals found out its ALS drug Relyvrio didn't work, the company took the unusual step of voluntarily pulling it off the market.
An Alzheimer's drug is on the way, but getting it may still be tough. Here's why
The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.